PRE VS SYRS Stock Comparison
Performance
PRE10/100
10/100
PRE returned -86.81% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
SYRS10/100
10/100
SYRS returned -32.17% in the last 12 months. Based on SPY's performance of -11.19%, its performance is below average giving it a score of 10 of 100.
Technicals
PRE36/100
36/100
PRE receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.
SYRS36/100
36/100
SYRS receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.
Earnings
PRE44/100
44/100
PRE has missed earnings 2 times in the last 20 quarters.
SYRS10/100
10/100
SYRS has missed earnings 7 times in the last 20 quarters.
Profit
PRE13/100
13/100
Out of the last 10 quarters, PRE has had 2 profitable quarters and has increased their profits year over year on 1 of them.
SYRS10/100
10/100
Out of the last 20 quarters, SYRS has had 0 profitable quarters and has increased their profits year over year on 1 of them.
Volatility
PRE55/100
55/100
PRE has had a higher than average amount of volatility over the last 12 months giving it a score of 54 of 100.
SYRS45/100
45/100
SYRS has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.
Analyst Price Targets
PRE
"Analyst Price Targets" not found for PRE
SYRS75/100
75/100
7 analysts offer 12-month price targets for SYRS. Together, they have an average target of 30, the most optimistic target put SYRS at 30 within 12-months and the most pessimistic has SYRS at 30.
All score calculations are broken down here to help you make more informed investing decisions
Prenetics Global Limited Class A Ordinary Share Summary
Nasdaq / PRE
Healthcare
Medical - Diagnostics & Research
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Syros Pharmaceuticals, Inc. Common Stock Summary
Nasdaq / SYRS
Healthcare
Biotechnology
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare PRE to other companies in the same or a similar industry.